# Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

> **NCT04524611** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 527 (actual)

## Conditions studied

- Crohn's Disease (CD)

## Interventions

- **DRUG:** Risankizumab
- **DRUG:** Risankizumab
- **DRUG:** Ustekinumab
- **DRUG:** Ustekinumab

## Key facts

- **NCT ID:** NCT04524611
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-09-30
- **Primary completion:** 2028-02
- **Final completion:** 2028-02
- **Target enrollment:** 527 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04524611

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04524611, "Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04524611. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*